Intravenous administration of infliximab results in serum levels that are proportional to the dose in patients suffering from a variety of inflammatory diseases. Infliximab treatment is characterized by a clini cal response that occurs as early as 2 weeks following the first infusion. The maintenance of the clinical response correlates with the presence of detectable infliximab concentrations of > 1 ^g/ml in the serum at trough which can be maintained by infusions every 8 weeks in most patients.
Formation of antibodies against infliximab has been observed in patients, and can lead to infusion reactions and faster elimination of the antibody from the circulation. While routes of administration other than infusion have been demonstrated to result in clinical benefit for patients, infliximab is commercially available only in the intravenous formulation.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.